Assembly Biosciences Inc
$ 27.36
-0.44%
11 Feb - close price
- Market Cap 434,655,000 USD
- Current Price $ 27.36
- High / Low $ 27.50 / 26.08
- Stock P/E N/A
- Book Value 11.55
- EPS -4.60
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.37 %
- 52 Week High 39.71
- 52 Week Low 7.75
About
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$47.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-06 | 2025-05-06 | 2025-03-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-01-31 | 2023-11-08 | 2023-08-09 | 2023-05-04 | 2023-03-22 |
| Reported EPS | -0.72 | -1.33 | -1.17 | -1.57 | -1.51 | -2.05 | -1.66 | -2.15 | -0.27 | -0.32 | -0.37 | -0.46 |
| Estimated EPS | -1.57 | -1.61 | -1.6 | -1.75 | -2.02 | -2.23 | -3.23 | -2.88 | -0.23 | -0.29 | -0.35 | -0.45 |
| Surprise | 0.85 | 0.28 | 0.43 | 0.18 | 0.51 | 0.18 | 1.57 | 0.73 | -0.04 | -0.03 | -0.02 | -0.01 |
| Surprise Percentage | 54.1401% | 17.3913% | 26.875% | 10.2857% | 25.2475% | 8.0717% | 48.6068% | 25.3472% | -17.3913% | -10.3448% | -5.7143% | -2.2222% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASMB
2026-02-07 00:36:00
This article provides an AI-generated analysis of Assembly Biosciences Inc. (NASDAQ: ASMB), highlighting positive near-term sentiment within a long-term bullish context, despite a weak mid-term bias. It outlines key findings, volatility zones, and three distinct institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels to assist traders in tactical decision-making.
2026-02-04 08:58:41
Assembly Biosciences (NASDAQ:ASMB) saw its share price trade above its 200-day moving average, reaching $28.35. The stock last traded at $28.24 with a volume of 118,749 shares. Analysts have given ASMB an average rating of "Moderate Buy" with a consensus target price of $41.00, despite the company missing its last quarterly earnings estimates.
2026-01-27 09:58:51
Assembly Biosciences (NASDAQ:ASMB) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $41.00. The company recently reported an EPS miss of ($0.72) and revenue beat of $10.79 million, but remains unprofitable. Institutional investors have significantly adjusted their holdings in ASMB, reflecting ongoing interest in the clinical-stage biotechnology company focused on HBV/HDV therapies.
2026-01-26 23:28:00
This article provides a price-driven insight for Assembly Biosciences Inc. (NASDAQ: ASMB), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
2026-01-22 10:27:48
Assembly Biosciences (NASDAQ:ASMB) shares dropped 27% in the last month, but the stock still shows a 76% gain over the past year. Despite a price-to-sales (P/S) ratio of 11.2x, which is comparable to the biotech industry median, the company faces concerns due to revenue growth being lower than competitors and analysts forecasting only 4.0% annual revenue growth while the industry is expected to grow by 126%. This discrepancy suggests that while investors are less bearish than analysts, the current P/S ratio might be unsustainable given the weaker growth outlook.
2026-01-21 00:27:57
Assembly Biosciences has announced interim results from its ongoing Phase 1a clinical trials for ABI-1179 and ABI-5366. The biotechnology company is developing these drug candidates for undisclosed therapeutic areas, and the preliminary findings will inform their further clinical development.
